Activating mutations in the EGFR gene are detectable in only a small minority of NSCLC patients but it is these patients who selectively respond to EGFR-directed therapy (Saintigny and Burger, 2012). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.